Neutrophil:Lymphocyte Ratio as a Predictive Factor for Success of Nephron-Sparing Procedures in Patients with Emphysematous Pyelonephritis

中性粒细胞与淋巴细胞比值作为预测气肿性肾盂肾炎患者肾单位保留手术成功率的指标

阅读:1

Abstract

INTRODUCTION: We studied the value of neutrophil:lymphocyte ratio (NLR) in predicting the success of nephron-sparing procedures in management of emphysematous pyelonephritis. METHODS: In this single-center retrospective study, patients underwent nephron-sparing procedures between 2007 and 2014. Severity was graded by Huang-Tseng classification. Thrombocytopenia, acute renal failure (ARF), shock, altered sensorium, and admission NLR were evaluated for predictive value for successful outcomes. Receiver operating characteristic curves were plotted to determine optimal cutoff of NLR for differentiating successful and unsuccessful outcomes. Two-sided p values were calculated with the χ(2) test. Factors that were significant on univariate analysis were combined in a model with NLR. RESULTS: Sixteen patients, 14 (87.5%) of whom were female and 14 (87.5%) of whom had diabetes, were included. Ten (63%) had severe emphysematous pyelonephritis. The optimal cutoff of NLR was 5. Four (44%) of 9 patients with NLR above 5 had unfavorable outcomes compared with none of 7 with NLR of 5 or less, giving a risk ratio of 1.8 (95% confidence interval [CI]= 1.01-3.22, p = 0.0417). Area under the curve for NLR alone was 0.77 (95% CI = 0.55-0.99, p = 0.014). High NLR and ARF were the only factors predicting unsuccessful outcome (p = 0.0417 each). When these were combined in a model (NLR as continuous variable), the area under the curve increased to 0.92. CONCLUSION: NLR is a useful predictive marker in emphysematous pyelonephritis. Its predictive value increases when combined with presence or absence of ARF. In patients with high NLR and ARF, the threshold for considering nephrectomy should be low.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。